1. Present
1.1. Niggles
1.1.1. High risk
1.1.1.1. 9-5 MF service
1.1.1.1.1. 25 years out of date at least
1.1.1.2. 9-5 MF service
1.1.2. Systemic cancers
1.1.2.1. Admission errors
1.1.2.2. Adverse Drug reaction MALdocumentation
1.1.2.3. Patient
1.1.2.4. Patient
1.1.2.4.1. Poorly
1.1.3. Poor new drug regulation
1.1.3.1. Adhoc adoption new drug technologies
1.1.3.2. Heavy pharmaceutical influence
1.1.3.3. Lack of accountability re costs of new technologies
1.1.3.4. Need mindshift
1.1.3.4.1. from
1.1.3.4.2. to
1.1.4. Regulatory/Professional silos
1.2. Nuggets
1.2.1. Pharmacists
1.2.1.1. Highly educated
1.2.1.2. Highly motivated
1.2.1.3. Hungry for MDT
1.2.1.4. National network (HPAI)
2. Future
2.1. Nice ifs
2.1.1. People
2.1.1.1. Technicians
2.1.1.1.1. Develop roles
2.1.1.1.2. Regulated
2.1.1.1.3. Recognised
2.1.1.1.4. Reimbursed
2.1.1.2. Pharmacists
2.1.1.2.1. MDT Norm
2.1.1.2.2. Prescribers
2.1.1.2.3. New specialism
2.1.1.2.4. Schools
2.1.2. 21st century
2.1.2.1. Technology
2.1.2.1.1. Well developed elsewhere
2.1.3. Value focus
2.1.3.1. Cost/benefit assessments
2.1.3.1.1. National level
2.1.3.1.2. National level
2.1.4. Patients
2.1.4.1. Part of service planning & strategy
2.2. No nos
2.2.1. MF 9-5 model persists
2.2.1.1. Extinction